DOCSLIB.ORG

Molecular Medicine Partnership Unit

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Medicine Partnership Unit MMPU Molecular Medicine Partnership Unit Today’s research for tomorrow’s medicine Molecular Medicine Partnership Unit A pioneering joint venture between the Medical Faculty of the University of Heidelberg and the European Molecular Biology Laboratory Contents The Molecular Medicine Partnership Unit (MMPU) 03 The MMPU within a changing paradigm of medical research 04 The MMPU approach: From the bedside to the research lab and back again 05 The Partners 06 MMPU research themes 07 ■ Diseases of mRNA metabolism 08 ■ Cystic fibrosis/Chronic airway disease 10 ■ Pathogenesis of colorectal cancer and development of novel approaches for early detection, diagnosis and prevention 12 ■ Iron homeostasis in health and disease 14 ■ Cell biology and disorders of cholesterol homeostasis 16 Getting involved in the MMPU 18 The MMPU is a collaboration between two renowned institutes located in Heidelberg, Germany. The cover image represents the city’s iconic “old bridge” against a backdrop of highly magnified cells and tissues. 03 The Molecular Medicine Partnership Unit (MMPU) The Molecular Medicine Partnership Unit is a collaboration between two institutions with world-renowned expertise in the life sciences and medicine: the European Molecular Biology Laboratory (EMBL) and the Medical Faculty of the University of Heidelberg. Its primary aim is to speed the transformation of remarkable ongoing discoveries in the biomedical sciences into applications that can be used for the development of personalized medicine strategies. Founded in 2002, the MMPU currently comprises five international research teams, jointly headed by a principal investigator from each organization and staffed by medical doctors, research associates, post- doctoral fellows, PhD students and technicians from both institutions. In this unique and stimulating setting, basic and clinical researchers work side-by-side to discover the molecular mechanisms that underlie com- mon diseases. The MMPU is co-directed by Prof. Andreas Kulozik from the Angelika-Lautenschläger Hospital for Children and Adolescents at the University of Heidelberg and by Prof. Matthias Hentze from EMBL, and is housed in the Otto-Meyerhof-Zentrum on the Medical Campus of the University of Heidelberg. Three elements are essential in the MMPU’s approach ■ a focus on important classes of diseases that makes optimum use of scientific expertise and clinical knowledge ■ a combination of clinical and molecular knowledge with the most sophisticated technologies and methodologies ■ the participation of scientists with a commitment to creativity and success “A translational approach to biomedical research will speed up new discoveries, allowing patients to benefit from research findings sooner.” Andreas Kulozik, Co-Director MMPU “Molecular Medicine provides great opportunities both for medicine and for basic science: medicine will benefit by achieving a deep molecular understanding of important diseases and basic science will gain important models to understand key biological processes.” Matthias Hentze, Co-Director MMPU 04 In the MMPU, basic and clinical researchers work side by side to understand the fundamental mechanisms behind a number of serious, widespread diseases. For MMPU collaborators, the road to understanding disease begins and ends with patients. The MMPU within a changing paradigm of medical research Medicine and the molecular life systems interact to transform a drug targets, or predict the likely sciences spring from different trad- healthy cell into a diseased one, effects of a treatment. itions that are only now coming or vice versa. But the past decade together in a unified approach to has seen a boom in the develop- “Molecular medicine” aims to human health. Modern medicine ment of new technologies capable draw together laboratory and clin- arose when scientists learned that of analyzing processes at the level ical research in a new approach microorganisms cause infectious of cells and organisms. based on an understanding of diseases and discovered ways to the basic mechanisms that cause combat them using vaccines and Genome projects have provided a disease. Achieving this vision drugs such as antibiotics. But complete catalogue of the genes requires bringing together two cul­­ today the major killers in industrial- of humans and many other organ- tures with different approaches to ized nations – and increasingly isms; microarrays and proteomic questions of health and disease, the developing world – stem from platforms yield a census of all the and different systems of education defects within our own cells. molecules active in a cell or tissue and working styles. The MMPU’s Treating them will require a deep and can be used, for example, to strategy relies on the formation of understanding of how genes, compare their behaviour in states close-knit teams involving a basic proteins, and other molecules of health and disease, or their and clinical researcher and their contribute to disease, and new response to drugs or other treat- groups, encouraging the use and safe methods of altering their ments. Sophisticated imaging and development of innovative technol- activity in patients. screening techniques have auto- ogies, and providing new types of mated the search for molecular training for the next generation of This approach follows decades of functions and substances that “physician-scientists”. systematic work in laboratories to can be used to manipulate them. discover molecules and learn their The new science of bioinformat- functions. Until recently, it has ics and systems biology integrates been difficult to observe how the all of this information into models elements of complex biological that can be used to search for new - 05 The MMPU approach: From the bedside to the research lab and back again The MMPU builds on existing, well- MMPU teams bring together med- MD degrees. EMBL also provides established research and clinical ical doctors, clinical researchers, affiliation for MMPU members groups, drawing them into collab- molecular biologists, physicists, to the EMBL International PhD orative teams and offering several chemists, engineers, computer Programme (EIPP) and the EMBL types of practical support as they scientists and other specialists Interdisciplinary Postdocs (EIPOD) take a unified approach to disease from across the world to solve programme, while the Medical processes. MMPU groups have challeng ing biological problems Faculty provides access to its unrestricted access to a complete that are typically difficult to Postdoc Fellowship Programme. range of some of the most power- address in any single clinical or These formal structures are com- ful and innovative services and laboratory setting. Support is plemented by international con- facilities available in the world, offered to research projects on the ferences, courses, seminar series housed within the University of basis of excellence. and other events in which part- Heidelberg network of institutes ners can keep abreast of devel- and clinics and the EMBL. This Such multidisciplinary teams opments in their field. The MMPU includes a number of core facilities are likely to become the stand- also hosts public research days, with state-of-the-art technol ogies, ard in biomedical research in the organized twice a year, aimed at screening platforms, a range of future, which will require a new communi cating the exciting dis- established animal models for gener ation of “physician-scientists” coveries coming from the collabo- human diseases, tissue samples who are trained to work on trans- ration to the wider scientific and and data from patients at various lational themes. The MMPU medical communities. stages of a disease, access to offers hands-on practical training clinical trials, etc. A number of through the University’s Medical innovative methods and technol- Faculty degree track as well as ogies have been developed within through a dedicated interdiscip- the teams themselves, a process linary teaching seminar series which is strongly encouraged aimed at students preparing for within the MMPU. Master’s, Bachelor’s, PhD and 06 The Partners The MMPU is a partnership be- methods in the life sciences and has tween EMBL and the Medical Faculty an active technology transfer pipe- of the University of Heidelberg, line to translate discoveries into drawing together a growing staff applications that benefit society. of currently more than 50 experts recruited from across the world. The Medical Faculty of the University of Heidelberg, founded The European Molecular Biology in 1386, forms part of one of the Laboratory, dedicated to basic oldest and most distinguished research in the molecular life sci- academic institutions in Europe. ences, is internationally recognized The Faculty fosters close links The EMBL Advanced Training Centre on as one of the world’s foremost between research labs and hos- the EMBL campus research institutions. Established pital wards, permitting the swift in 1974, EMBL is funded by pub- implementation of newly acquired lic research monies from 20 knowledge from clinical studies. European member states, and as- Its practically oriented modern sociate member state, Australia, teaching methods and systematic and comprises almost 100 inde- encouragement of young re- pendent groups covering the spec- searchers makes it one of the trum of molecular biology. Groups leading institutions for medical work either at the Main Laboratory research and training in Germany. in Heidelberg, or at one of four out- In 2007,
Load more

Recommended publications
  • NEWSLETTER – March 2016
    BRITISH SOCIETY FOR PROTEOME RESEARCH www.bspr.org UK Charity Number 1121692 Registered Company No.6319769 NEWSLETTER – March 2016 BSPR 2016 – PROTEOMIC APPROACHES TO HEALTH AND DISEASE University of Glasgow – 25-27 July 2016 th th The 2016 meeting of the Society will be held in the Western Infirmary Lecture Theatre building from Mon 25 – Wed 27 July 2016. For up to date information: (www.bspr.org/node/527) Abstract submission now open. Deadline: Mon 6th May. Registration opening shortly! Speakers include: Plenary - Matthias Mann – Max-Planck Institute for Biochemistry, Martinsried (GER) Rob Beynon (BSPR Lecturer 2016) – University of Liverpool (UK) Keynote: -Cancer: Judit Villen – University of Washington, Genome Sciences (US) Integration Omics: David Matthews – University of Bristol (UK) Metabolic disease: Harald Mischak – University of Glasgow (UK) Development and ageing: Xavier Druart - French Nat’l Inst for Agricultural Res, Nouzilly (FR) Nutrition/Lifestyle & Food Security: David Eckersall - University of Glasgow (UK) Infectious disease and Microbiome: Frank Schmidt – University of Greifswald (GER) New Technologies - Matthias Hentze – EMBL Heidelberg (GER) Data Analysis – Maria Martin – EMBL-EBI Cambridge (UK) Translation – Chris Sander, New York (US) More than 20 abstracts will be selected for oral presentation! Bursaries and Awards BSPR 2016 - The Society will be awarding the MJ Dunn Fellowship for attendance at BSPR 2016, and will also be awarding Bursaries to student members (£250) to enable them to attend a conference of their choice, including BSPR 2016. 10th European Summer School EMBO Workshop “Advanced Proteomics”, July 31st – August 6th, 2016. The Society will be awarding one or two bursaries (residential registration fee) to student members to enable them attend this workshop which will be held in Kloster Neustift, Brixen/Bressanone, South Tyrol, Italy.
    [Show full text]
  • The Helicase Ded1p Controls Use of Near-Cognate Translation Initiation Codons in 5Utrs
    The helicase Ded1p controls use of near- cognate translation initiation codons in 5# UTRs The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Guenther, Ulf-Peter et al. "The helicase Ded1p controls use of near- cognate translation initiation codons in 5# UTRs." Nature 559, 7712 (June 2018): 130–134. © 2018 Macmillan Publishers Ltd., part of Springer Nature As Published http://dx.doi.org/10.1038/s41586-018-0258-0 Publisher Springer Science and Business Media LLC Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125996 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2018 December 27. Published in final edited form as: Nature. 2018 July ; 559(7712): 130–134. doi:10.1038/s41586-018-0258-0. The helicase Ded1p controls use of near-cognate translation initiation codons in 5′UTRs Ulf-Peter Guenther1,*, David E. Weinberg2,3,*, Meghan M. Zubradt2,4,*, Frank A. Tedeschi1, Brittany N. Stawicki1, Leah L. Zagore1, Gloria A. Brar5, Donny D. Licatalosi1, David P. Bartel3, Jonathan S. Weissman2,4, and Eckhard Jankowsky1,6,7 1Center for RNA Science and Therapeutics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA 2Department of Cellular and Molecular Pharmacology, University of California,
    [Show full text]
  • Future Plans from the New Head of Personnel What's It Really Like to Come to EMBL As a Predoc? Official: Nordic EMBL Partnersh
    41 EMBL October 2007 &Newslettercetera of the European Molecular Biology Laboratory What’s it really like to come to EMBL as a predoc? A predoc’s first few weeks at EMBL can be a culture shock. It often means coping with a new language, finding a new home, meeting so many people that you can’t remember any names and, more often than not, leaving friends behind. But it’s also the beginning of a brilliant opportunity. Inside, Mateusz Putyrski, a new PhD in Carsten Schultz’s lab at EMBL Heidelberg in August, talks about how to settle in smoothly – and once settled in, how to stay connected to the outside world. page 5 Future plans from the new Head of Personnel One of Yann Chabod’s first tasks as Head of the Personnel department will be to oversee the imple- mentation of its new SAP HR database early next year, replacing the old PAISY system, which will be, as he says, “a big, big change in the way we do everything. The day-to-day job is being done well already. We’ve got very good people here but we can still improve the quality of our customer service with the right tools. I’m here to help and support them... and to learn about this new field!” page 3 Official: Nordic EMBL Partnership for Molecular Medicine University rectors and ministry and council representatives from Scandinavia came to EMBL Heidelberg on October 3 for the official agreement signing of the Nordic EMBL Partnership for Molecular Medicine. The partnership will combine the recognised, complementary strengths of all four partners to collaborate closely in the area of molecular medicine, tackling some of the most challeng- ing problems in biomedicine.
    [Show full text]
  • Program Information
    RNA 2021 The 26th Annual Meeting of the RNA Society On-line May 25–June 4, 2021 RNA 2021 On-Line The 26th Annual Meeting of the RNA Society CORRECT THE MESSAGE CHANGE A LIFETM Locanabio’s CORRECTXTM platform is pioneering a new class of gene therapies by correcting the th th May 25 – June 4 , 2021 dysfunctional RNA that causes a broad range of neurodegenerative, neuromuscular and retinal diseases Gene Yeo – University of California San Diego, USA Katrin Karbstein – Scripps Research Institute, Florida, USA V. Narry Kim – Seoul National University, South Korea Anna Marie Pyle – Yale University, USA Xavier Roca – Nanyang Technological University, Singapore Jörg Vogel – University of Würzburg, Germany RNA 2021 • On-line GENERAL INFORMATION Citation of abstracts presented during RNA 2021 On-line (in bibliographies or other) is strictly prohibited. Material should be treated as personal communication and is to be cited only with the expressed written ® consent of the author(s). The Sequel IIe System NO UNAUTHORIZED PHOTOGRAPHY OF ANY MATTER PRESENTED DURING THE ON-LINE MEETING: To encourage sharing of unpublished data at the RNA Society Annual Meeting, taking of photographs, screenshots, videos, and/or downloading or saving Reveal the functional e ects any material is strictly prohibited. of alternative splicing with USE OF SOCIAL MEDIA: The official hash tag of the 26th Annual Meeting of the RNA Society is full-length transcript sequencing #RNA2021. The organizers encourage attendees to tweet about the amazing science they experience during the meeting. However, please respect these few simple rules when using the #RNA2021 hash tag, or when talking about the meeting on Twitter and other social media platforms: 1.
    [Show full text]
  • The Cell's 'New World': First Complete Atlas of RNA-Binding Proteins 1 June 2012
    The cell's 'New World': First complete atlas of RNA-binding proteins 1 June 2012 In one of the most famous faux pas of exploration, will enable scientists to study how the cell's Columbus set sail for India and instead machinery adapts to stressful situations, responds 'discovered' America. Similarly, when scientists at to drugs or to changes in metabolism, or is altered the European Molecular Biology Laboratory in disease. (EMBL) in Heidelberg, Germany, set out to find enzymes - the proteins that carry out chemical reactions inside cells - that bind to RNA, they too Provided by European Molecular Biology found more than they expected: 300 proteins Laboratory previously unknown to bind to RNA - more than half as many as were already known to do so. The study, published online today in Cell, could help to explain the role of genes that have been linked to diseases like diabetes and glaucoma. "We are very excited that, unlike Columbus, we found what we were looking for: well-known enzymes that bind to RNA," says Matthias Hentze, who led the study at EMBL with Jeroen Krijgsveld. "But we never thought there was still so much unexplored territory, so many of these RNA- binding proteins to be discovered." Almost 50 of the new proteins Hentze and Krijgsveld found are encoded by genes known to be mutated in patients suffering from a variety of diseases, from diabetes and glaucoma to prostate and pancreatic cancers. This finding opens new avenues for researchers studying these disorders. It raises the possibility that such conditions could be caused by a malfunction not in the protein's previously established function, but in its potential role in RNA control.
    [Show full text]
  • Curriculum Vitae Professor Dr. Matthias W. Hentze
    Curriculum Vitae Professor Dr. Matthias W. Hentze Name: Matthias W. Hentze (Prof. Dr. med., Dr. h. c.) Born: 25 January 1960 Image: EMBL Photolab Massimo del Pete Research Priorities: Control of protein synthesis, Post-transcriptional control of gene regulation and its disorders in genetic diseases, Regulation of human iron metabolism, Metabolic processes and gene regulation, Riboregulation Matthias Hentze is a physician. For many years, his research focused on the understanding of posttranscriptional gene regulation, especially the control of protein synthesis. His work has also provided fundamental insights into the molecular mechanisms governing iron homeostasis and diseases of altered iron metabolism. At present, Hentze investigates connections between gene regulation and metabolism. Following their discovery of hundreds of new RNA-binding proteins, his team investigates the process of riboregulation, a novel biological control mechanism that they also recently described. Academic and Professional Career since 2013 Director, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany since 2005 Associate Director, European Molecular Biology Laboratory (EMBL) since 2005 Professor (apl.), Medical Faculty, University of Heidelberg (Ruprecht-Karls- Universität), Germany since 2002 Co-Director “Molecular Medicine Partnership Unit”, University of Heidelberg / EMBL 2001 - 2005 Unit Coordinator “Training, Partnership & Endowment”, EMBL since 1998 Senior Scientist, EMBL 1996 - 2005 Dean of Graduate Studies, EMBL Nationale Akademie der Wissenschaften Leopoldina www.leopoldina.org 1 1990 Habilitation in “Medical Molecular Biology”, Faculty for Theoretical Medicine, University of Heidelberg, Hermany since 1989 Group Leader, EMBL 1987 - 1989 Visiting Associate, National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA 1985 - 1987 Guest Researcher, National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA 1985 Attending Physician, Internal Medicine, St.
    [Show full text]
  • EMBC Annual Report 2008
    EMBO | EMBC annual report 2008 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Hermann Bujard, EMBO 5 preface by Tim Hunt, EMBO Council 8 preface by Peter Weisbeek & Krešimir Pavelić, EMBC 9 past & present timeline & brief history 12 EMBO | EMBC | EMBL aims 14 EMBO actions 2008 17 EMBC actions 2008 21 EMBO & EMBC programmes and activities fellowship programme 24 courses & workshops programme 25 young investigator programme 26 installation grants 27 science & society programme 28 EMBO activities The EMBO Journal 32 EMBO reports 33 Molecular Systems Biology 34 EMBO Molecular Medicine 35 journal subject categories 36 national science reviews 37 The EMBO Meeting 38 women in science 39 gold medal 40 award for communication in the life sciences 41 plenary lectures 42 information support & resources 43 public relations & communications 44 European Life Sciences Forum (ELSF) 45 ➔ 2 table of contents appendix EMBC delegates and advisers 48 EMBC scale of contributions 55 EMBO council members 2008 56 EMBO committee members & auditors 2008 57 EMBO council members 2009 58 EMBO committee members & auditors 2009 59 EMBO members elected in 2008 60 advisory editorial boards & senior editors 2008 72 long-term fellowship awards 2008 76 long-term fellowships: statistics 94 long-term fellowships 2008: geographical distribution 96 short-term fellowship awards 2008 98 short-term fellowships: statistics 116 short-term fellowships 2008: geographical distribution 118 young investigators
    [Show full text]
  • EMBO Facts & Figures
    excellence in life sciences young investigators|courses,workshops,conference series & symposia|installation grantees|long-term fellows|short-term fellows|policy, science & society|the EMBO Journal|EMBO reports|molecular systems biology|EMBO molecular medicine|global exchange|gold medal|the EMBO meeting|women in science| EMBO reports|molecular systems biology|EMBO molecular medicine|global exchange|gold medal|the EMBO meeting|women in science|young investigators|courses,workshops,conference series & symposia|installation grantees|long-term fellows|short-term fellows|policy, science & society|the EMBO Journal| global exchange|gold medal|the EMBO meeting|women in science|young investigators|long-term fellows|short-term fellows|policy, science & society|the EMBO Journal|courses,workshops,conference series & symposia|EMBO reports|molecular systems biology|EMBO molecular medicine|installation grantees| EMBO molecular medicine|installation grantees|long-term fellows|gold medal|molecular systems biology|short-term fellows|the EMBO meeting|womenReykjavik in science|young investigators|courses,workshops,conference series & symposia|global exchange|EMBO reports|policy, science & society|the EMBO Journal| gold medal|the EMBO meeting|women in science|young investigators|courses,workshops,conference series & symposia|global exchange|policy, science & society|the EMBO Journal|EMBO reports|molecular systems biology|EMBO molecular medicine|installation grantees|long-term fellows|short-term fellows| courses,workshops,conference series & symposia|global
    [Show full text]
  • Research at a Glance 2011
    European Molecular Biology Laboratory Research at a Glance 2011 European Molecular Biology Laboratory Research at a Glance 2011 Research at a Glance 2011 Contents 4 Foreword by Iain Mattaj, EMBL Director General 5 EMBL Heidelberg, Germany 6 Cell Biology and Biophysics Unit 17 Developmental Biology Unit 26 Genome Biology Unit 35 Structural and Computational Biology Unit 48 Directors’ Research 52 Core Facilities 61 EMBL-EBI, Hinxton, UK European Bioinformatics Institute 89 EMBL Grenoble, France Structural Biology 100 EMBL Hamburg, Germany Structural Biology 109 EMBL Monterotondo, Italy Mouse Biology 116 Index Foreword by EMBL‘s Director General EMBL – Europe’s leading laboratory for basic research in molecular biology The vision of the nations which founded the European Molecular Biology Laboratory was to create a centre of excellence where Europe’s best brains would come together to conduct basic research in molecular biology. During the past three decades, EMBL has grown and developed substantially, and its member states now number twenty-one, including the first associate member state, Australia. Over the years, EMBL has become the flagship of European molecular biology and has been continuously ranked as one of the top research institutes worldwide. EMBL is Europe’s only intergovernmental laboratory in the life sciences and as such its missions extend be- yond performing cutting-edge research in molecular biology. It also offers services to European scientists, most notably in the areas of bioinformatics and structural biology, provides advanced training to researchers at all levels, develops new technologies and instrumentation and actively engages in technology transfer for the ben- efit of scientists and society.
    [Show full text]
  • MOSBACHER Kolloquium PROGRAM
    GBM 66. Mosbacher Kolloquium Metals in Biology - Cellular Functions and Diseases March 26 - 28, 2015 preliminary Program Organization Scientific Organizers: Martina Muckenthaler Ruprecht Karls University Heidelberg, Germany Roland Lill Philipps University Marburg, Germany Ralf-R. Mendel Technische Universität Braunschweig, Germany Conference Office: Sabine Hähnke-Metzen Anke Lischeid Tino Apel German Society for Biochemistry and Molecular Biology (GBM) Mörfelder Landstr. 125 60598 Frankfurt am Main Germany Tel +49 69 660567 0 Fax + 49 69 660567 22 [email protected] www.gbm-online.de Like it on Facebook 2 Table of Contents Organization 2 Welcome address 4 Program at a glance 5 Program 9 Prize lectures 14 Students for students 16 Social program 17 General remarks Accommodation 18 Conference office 18 Internet access 18 Lunch & coffee breaks 19 Posters 19 Industrial exhibition 19 Registration 20 Proceedings 21 Venue 21 Exhibitors 22 Sponsors 23 3 Welcome Address Dear Colleagues, The traditional spring meetings of the German Society for Biochemistry and Molecular Biology (GBM) are held annually in the picturesque town of Mosbach to promote the exchange of scientific ideas and to foster the educa- tion of young scientists. The scientific theme of the 66th meeting is “Metals in Biology: Cellular functions and diseases”. Metals such as iron, copper, molybdenum, mangane- se and zinc participate in many biochemical and cell biological processes. More than 40% of the cellular proteins bind a functionally critical metal or metal-co- factor. Hence, acquisition, intracellular distribution, and protein insertion of metals are essential for cell viability. Conversely, unbound metals are toxic, thus requiring sophisticated regulatory systems to assure adequate cellular uptake, storage and export.
    [Show full text]
  • EMBC Annual Report 2005
    EMBO | EMBC annual report 2005 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Frank Gannon, EMBO 4 preface by Susan Gasser, EMBO Council 6 preface by Marja Makarow, EMBC 8 past & present timeline 12 brief history 13 EMBO | EMBC | EMBL 14 EMBO actions 2005 17 EMBC actions 2005 19 EMBO & EMBC programmes and activities fellowship programme 23 courses & workshops programme 24 world activities 25 young investigator programme 26 women in the life sciences 27 science & society programme 28 electronic information programme 29 EMBO activities The EMBO Journal 32 EMBO reports 33 Molecular Systems Biology 34 journal subject categories 35 national science reviews 36 gold medal 37 award for communication in the life sciences 38 sectoral meetings 39 plenary lectures 40 communications offi ce 41 European Life Sciences Forum (ELSF) 42 ➔ 2 table of contents appendix EMBC delegates and advisers 46 EMBC scale of contributions 53 EMBO council members 2005 54 EMBO committee members & auditors 2005 55 EMBO council members 2006 56 EMBO committee members & auditors 2006 57 EMBO members elected in 2005 58 advisory editorial boards & senior editors 2005 66 long-term fellowship awards 2005 70 long-term fellowships: statistics 84 long-term fellowships 2005: geographical distribution 86 short-term fellowship awards 2005 88 short-term fellowships: statistics 102 short-term fellowships 2005: geographical distribution 104 young investigators 2005 106 young investigators 2000 – 2004 107 young investigators: statistics 108 young investigator lectures 2005 110 courses | workshops | conferences | symposia 2005 112 plenary lectures 2005 118 participation of women in EMBO activities: statistics 120 EMBO staff 124 events in 2006 courses | workshops | conferences | conference series | symposia 2006 128 plenary lectures 2006 134 other EMBO events 2006 136 organisations and acronyms 138 ➔ 3 preface EMBO & EMBC 2005 An awkward time warp surrounds annual 1200 applications for long-term fellowships and reports.
    [Show full text]
  • Press Release
    Press Release The cell’s ‘New World’ First complete atlas of RNA-binding proteins could point to function of genes linked to diseases Heidelberg, 31 May 2012 – In one of the most famous faux pas of exploration, Columbus set sail for India and instead ‘discovered’ America. Similarly, when scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, set out to find enzymes – the proteins that carry out chemical reactions inside cells – that bind to RNA, they too found more than they expected: 300 proteins previously unknown to bind to RNA – more than half as many as were already known to do so. The study, published online today in Cell, could help to explain the role of genes that have been linked to diseases like diabetes and glaucoma. “We are very excited that, unlike Columbus, we found what we were looking for: well-known enzymes that bind to RNA,” says Matthias Hentze, who led the study at EMBL with Jeroen Krijgsveld. “But we never thought there was still so much unexplored territory, so many of these RNA-binding proteins Scientists catalogued all proteins that bind to RNA, finding 300 previously to be discovered.” unknown to do so. Almost 50 of the new proteins Hentze and Krijgsveld found are encoded by genes known to be mutated in patients suffering isolating all proteins that bind to RNA in living cells. The new from a variety of diseases, from diabetes and glaucoma to approach will have many further uses, as it can be applied prostate and pancreatic cancers. This finding opens new avenues to other cell types and conditions, to explore which proteins for researchers studying these disorders.
    [Show full text]